The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2023 | CheckMate 816: what does the data tell us?
Riyaz Shah, BSc(Hons), MBBS, FRCP, PhD, Kent Oncology Centre, Maidstone, UK, discusses the fundamental contribution of the CheckMate 816 trial (NCT02998528) in discerning the preoperative efficacy outcomes of three neoadjuvant chemotherapy cycles. Dr Shah highlights that although no new data was presented at the British Thoracic Oncology Group (BTOG) Annual Conference 2023, a poster reaffirming the treatments pathological complete response (CR) rate and event-free survival was presented at the conference. This interview took place at BTOG 2023 in Belfast, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
